Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL775115 | 0.79 | PNMT (0.46) | IDO1TSHRNPC1LMNAHTT | |
| SCHEMBL638587 | 0.78 | PNMT (0.46) | IDO1TSHRCYP3A4TP53PNMT | |
| SCHEMBL2359630 | 0.76 | TSHR (0.47) | TSHRCYP3A4LMNASMN1; SMN2TP53 | |
| SCHEMBL2095373 | 0.70 | CYP3A4 (0.40) | IDO1CYP3A4NPC1LMNAHTT | |
| SCHEMBL11242602 | 0.68 | CYP3A4 (0.36) | IDO1TSHRCYP3A4HTTSMN1; SMN2 | |
| SCHEMBL31568962 | 0.67 | CYP3A4 (0.48) | TSHRCYP3A4LMNATP53ALDH1A1 | |
| SCHEMBL345826 | 0.67 | CYP3A4 (0.48) | TSHRCYP3A4LMNATP53ALDH1A1 | |
| SCHEMBL671453 | 0.67 | PNMT (0.54) | IDO1TSHRCYP3A4PNMTALDH1A1 | |
| SCHEMBL2910000 | 0.67 | DPP4 (0.37) | TSHRCYP3A4NPC1LMNAHTT | |
| SCHEMBL27659190 | 0.66 | NOS2 (0.35) | HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119614-B2 | Substitution derivatives of N6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2012-02-21 | — | — | US | disclosed |
| EP-1348707-B1 | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy | USTAV EX BOTAN AV CR V V I I O (CZ) | 2010-08-25 | — | — | EP | disclosed |
| US-7745450-B2 | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy | INSTITUTE OF EXPERIMENTAL BOTANY (CZ) | 2010-06-29 | — | — | US | disclosed |
| US-20060166925-A1 | Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2006-07-27 | — | — | US | disclosed |
| US-20050080097-A1 | Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy | USTAV EXPERIMENTALNI BOTANIKY AV CR (INSTITUTE OF EXPERIMENTAL BOTANY ACADEMY OF | 2005-04-14 | — | — | US | disclosed |
| EP-1348707-A1 | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy | Ustav Experimentalni Botaniky AV CR (Institute of Experimental Botany Academy of Sciences of the Czech Republic) (CZ) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166925-A1 | Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | ADAR, ADORA2A, AMPD2 | IDO1 222/4885TSHR 1506/4885CYP3A4 3917/4885 |
| US-20050080097-A1 | Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy | CBR3, DHFR, AKR1C3 | IDO1 2607/4885TSHR 51/4885CYP3A4 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.